
An Updated **Meta-Analysis** of Randomized Controlled Trial Assessing the Effect of Neoadjuvant Chemotherapy in Advanced Gastric Cancer

	NAC		Contr	ol		Odds Ratio		Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	Year	M-H, Fixed, 95% CI
Yonemura 1993	5	29	1	26	0.6%	5.21 [0.57, 47.90]	1993	 •
Lygidakis 1999	14	39	5	19	3.0%	1.57 [0.47, 5.27]	1999	+-
Kobayashi 2000	57	91	49	80	13.4%	1.06 [0.57, 1.97]	2000	+
Wang 2000	12	30	7	30	2.9%	2.19 [0.72, 6.70]	2000	
Nio 2004	73	102	137	193	18.5%	1.03 [0.61, 1.75]	2004	+
Hartgrink 2004	6	27	10	29	5.1%	0.54 [0.17, 1.78]	2004	
Cunningham 2006	101	250	83	253	33.7%	1.39 [0.96, 2.00]	2006	•
Schuhmacher 2010	40	72	37	72	11.3%	1.18 [0.61, 2.28]	2010	+
Ychou2011	43	113	27	111	11.6%	1.91 [1.07, 3.40]	2011	-
Total (95% CI)		753		813	100.0%	1.32 [1.07, 1.64]		*
Total events	351		356					
Heterogeneity: Chi2 = 7	7.58, df = 8	B (P = 0	.48); l ² =	0%				1 1 1 1 500
Test for overall effect: 2	Z = 2.56 (F	o = 0.0	1)					0.002 0.1 1 10 500 Favours control Favours NAC

	NAC	Contr	Control		Odds Ratio		Odds Ratio	
Study or Subgroup	Events To	tal Events	Total	Weight	M-H, Fixed, 95% CI Y	/ear	M-H, Fixed, 95% CI	
Cunningham 2006	98 2	50 63	253	54.7%	1.94 [1.33, 2.85] 2	2006	-	
Schuhmacher 2010	36	72 29	72	20.8%	1.48 [0.77, 2.87] 2	2010	+•-	
Ychou2011	45 1	13 28	111	24.4%	1.96 [1.11, 3.47] 2	2011	-	
Total (95% CI)	4	35	436	100.0%	1.85 [1.39, 2.46]		*	
Total events	179	120						
Heterogeneity: Chi² = 0.54, df = 2 (P = 0.76); l² = 0%								
Test for overall effect: 2	z = 4.23 (P <	0.0001)					avours control Favours NAC	





NCCN Guidelines Version 2.2022 **Gastric Cancer**

NCCN Guidelines Index Table of Contents Discussion

